Skip to main content
LLY logo

Eli Lilly and Company (LLY) Stock: Price, Forecast & Analyst Target

Eli Lilly and Company (LLY) — MoonshotScore 98/100 (Exceptional band), calculated Nov 18, 2026. Price $1351.12 (-2.29%), as of the Nov 19, 2026 trading session; market cap $1.20T. Expected results Feb 3, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 245.65× (cash as of Sep 30, 2026) · expected results Feb 3, 2027

$1351.12 −$31.63 (-2.29%) Market Cap $1.20T

Eli Lilly and Company · LLY · NYSE · Healthcare · Drug Manufacturers - General

Research dated 2026-09-13: Eli Lilly sells prescription medicines across diabetes, oncology, immunology, neuroscience and pain, with product sales supplying nearly all revenue while collaborations remain ancillary. The case depends on whether rapid medicine-led growth can keep translating into profit and cash while Lilly funds research, production capacity and a debt-heavy balance sheet at a demanding valuation.

Price as of Nov 19, 2026

Key Statistics

98 of 100

MoonshotScore v2 · Eli Lilly and Company (LLY)

Exceptional
Business Quality Elite (97)
Financial Safety Fortress (93)
Valuation Rich (34)
Growth Durability Compounding (99)
Momentum Surging (92)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, a fortress balance sheet and elite growth, but an expensive valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Compounding; Momentum: Surging.

Price relative to book value is the main valuation drag relative to sector peers.

  • EPS beat 0 of the last 4 reports
  • expected results Feb 3, 2027
  • Altman Z 9.45 · Piotroski F 7

Holding back: a rich price

Helping: business quality, balance-sheet strength, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for LLY (58 recorded, newest six shown)
RecordedScoreBand
90Exceptional
98Exceptional
98Exceptional
98Exceptional
98Exceptional
98Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1351.12
Change on the day-2.29%
52-week range$850.51–$1475.25
Market capitalisation$1.20T—
Price / earnings (trailing)45.83
Shares traded on the day3.07M
Beta (volatility vs the S&P 500)0.45
Dividends per share (last 12 months)$6.92
Dividend yield (last 12 months)0.49%

Why Eli Lilly and Company scores 98

Dr. Mira Sol, the Stock Expert AI TV data character
Growth Durability carries the score; Valuation is what holds it back.
Dr. Mira Sol · Data scientist, Stock Expert AI TV (fictional AI character)
98Exceptional
  • Business Quality97
  • Financial Safety93
  • Valuation34
  • Growth Durability99
  • Momentum92

Share price, last 12 months +46.1%

$966.64 $1,412

What the price assumes

23.7% a year of free-cash-flow growth for ten years is what a $1.33T market value ( snapshot) asks for.

  • Price implies, next ten years23.7%
  • Free cash flow, last 5 years14.9%
  • Revenue, last 5 years21.6%
  • Analysts' revenue path, 2026–203011.5%

The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.

Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $19.66B. Inputs: FMP statements, estimates and quote.

How the stock reacts to earnings

EPS beat in 11 of the last 12 reports (2024–2026); the stock still fell the next session after 2 of those beats. Average first-session move: 8.2% either way.

  1. +2.7%Feb ’24
  2. +5.4%Apr ’24
  3. +15.5%Aug ’24
  4. -8.2%Oct ’24
  5. +4.3%Feb ’25
  6. -8.4%May ’25
  7. -16.2%Aug ’25
  8. +6.1%Oct ’25
  9. +1.7%Feb ’26
  10. +13.2%Apr ’26
  11. +6.8%Aug ’26
  12. +10.0%Oct ’26
Next-session move EPS beat (11) EPS miss (1)
Every report, with revenue and five-session moves
Moves run from the close before the report to the first and fifth closes after it.
ReportEPSRevenueNext session5 sessions
BeatBeat+10.0%+5.9%
BeatBeat+6.8%+9.4%
BeatBeat+13.2%+14.5%
BeatBeat+1.7%+1.2%
BeatBeat+6.1%+15.2%
BeatBeat-16.2%-8.3%
BeatIn line-8.4%-16.4%
Beat—+4.3%+3.5%
MissMiss-8.2%-14.1%
BeatBeat+15.5%+20.6%
BeatMiss+5.4%+5.5%
BeatBeat+2.7%+5.2%

Beats have usually been rewarded — 9 of 11 drew a higher close the next session.

What management is saying differently

Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.

  • New this call: “maintenance doses”, “disciplined approach” — none of them came up in Q2 FY2026.
  • Getting louder: “long term” (1 → 5 mentions), “lilly medicine” (2 → 4 mentions), “phase trials” (2 → 4 mentions).
  • Gone quiet: “incretin analogs”, “revenue growth” — regular themes last call, absent this time.
  • Tone: Cautious words such as “may”, “could” and “headwind” rose from 3.2 to 5 per 1,000 words, and confident words such as “record” and “strong” fell from 3.7 to 1.8.

Management chose more careful words than a quarter earlier. Tone shifts like this often show up in the numbers a quarter or two later.

Our track record on this stock

Since the score went from 97 to 98 while the share price moved +8.4% through .

MoonshotScore (0–100, band floors 45 · 65 · 80) Share price, scaled to its own range

The score has stayed in the Exceptional band across the stretch we have recorded; we grade each band change three months after it happens.

The crowd against our signals

  • Analysts: 74% of 46 rate it a buy; the average target sits +7.0% from the price of $1,351.
  • Last 90 days: 18 rating actions, every one a reaffirmation.
  • Our signals: Exceptional band; strongest pillar Growth Durability (99), weakest Valuation (34).

Here we and the crowd agree. Where we differ is on price: our Valuation reading is more cautious than the analysts' targets.

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $803, high $1,444, latest $1,351. 4 reported quarters marked, 4 above and 0 below the recorded estimate. 1 other dated event marked. $1,444 $803 high $1,444 Feb 4, 2026 · Earnings results · reported above the recorded estimate · close $1,0581Apr 30, 2026 · Earnings results · reported above the recorded estimate · close $9632Aug 5, 2026 · Earnings results · reported above the recorded estimate · close $1,1863Oct 29, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $1,4184Oct 29, 2026 · Earnings results · reported above the recorded estimate · close $1,4185 Oct 17, 2025 Nov 19, 2026 · $1,351 $803Oct 17, 2025$863Oct 31, 2025$1,025Nov 14, 2025$1,075Nov 28, 2025$1,028Dec 12, 2025$1,078Dec 26, 2025$1,064Jan 9, 2026$1,064Jan 23, 2026$1,058Feb 6, 2026$1,010Feb 20, 2026$990Mar 6, 2026$907Mar 20, 2026$936Apr 2, 2026$927Apr 17, 2026$963May 1, 2026$1,005May 15, 2026$1,105May 29, 2026$1,133Jun 12, 2026$1,208Jun 26, 2026$1,189Jul 10, 2026$1,196Jul 24, 2026$1,186Aug 7, 2026$1,255Aug 21, 2026$1,149Sep 4, 2026$1,153Sep 18, 2026$1,143Oct 2, 2026$1,257Oct 16, 2026$1,418Oct 30, 2026$1,444Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

Dated events ahead, in order, not to scaleDec 10, 2026, Dividend payment date; Feb 3, 2027, Next results due. Spacing is order only and carries no duration.Nov 19, 20261Dec 10, 20262Feb 3, 2027
  1. Dividend payment dateCompany record
  2. Next results dueProvider estimate

Management outlook

  • Based on a strong underlying performance across our portfolio, we now expect full year revenue to be between $91 and $92 billion We saw strength in The U.

    Lucas E. Montarce · Statement from

  • We expect non GAAP earnings per share of $35 to $36 This reflects an increase of $4.07 per share at the midpoint of the range before updates to the Q3 acquired IPR&D charges of $4.57 per share.

    Lucas E. Montarce · Statement from

How to read these dates

Events are in date order; the spacing is not a duration scale. A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

Read management statements

Other perspectives

Council score for Eli Lilly and Company (LLY): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Strong
Financial Safety Strong
Valuation Weak
Growth Durability Strong
Momentum Strong

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 21, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Moderate
Margin of Safety Overvalued
Profit Margin Strong
Debt/Equity Negative
ROE Strong
Gross Margin Strong

Read on: Nov 21, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company less favourably than the MoonshotScore does: Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as overvalued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Eli Lilly and Company (LLY), and what does it report?

Short answer · as of

Lilly is a commercial pharmaceutical manufacturer, not a development-stage biotechnology company waiting on an initial product. Its portfolio spans insulin and other diabetes therapies, cancer medicines, autoimmune treatments, and neurological and pain products; sales rise when those medicines gain use across their approved markets and fall when demand or commercialization weakens.

Reported revenue overwhelmingly measures product sales. Collaboration and other revenue contributes a much smaller stream, while research spending captures the continuing cost of replenishing and extending the medicine portfolio.

2 · Latest results

What do the latest results show for Eli Lilly and Company (LLY)?

The latest results extended a sharp expansion in revenue, gross profit and operating profit. Revenue reached a new high in the reported series, while net income and diluted earnings eased from the immediately preceding period despite stronger operating performance.

Research and selling expenses also rose, so the expanding top line is carrying heavier investment and commercialization spending. Recent reported revenue and adjusted earnings have repeatedly exceeded estimates, and management responded to higher revenue by raising its full-year revenue, margin and earnings outlook.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$24.40B Sep 30, 2026
Latest quarter · R&D
$4.25B Sep 30, 2026
Latest quarter · SG&A
$3.13B Sep 30, 2026
Latest quarter · FMP standardized operating result
$8.61B Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$24.40B$4.25B$3.13B$8.61B
Jun 30, 2026$22.97B$3.82B$3.43B$12.46B
Mar 31, 2026$19.80B$3.51B$2.93B$9.78B
Dec 31, 2025$19.29B$3.80B$3.13B$8.99B
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$24.40B Oct 29, 2026
Latest report · revenue estimate
$22.58B Oct 29, 2026
Latest report · revenue vs estimate
Above estimate Oct 29, 2026
Latest report · EPS vs estimate
Above estimate Oct 29, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Oct 29, 2026$24.40B$22.58B$7.4800$5.7100
Aug 5, 2026$22.97B$20.82B$8.3800$6.4000
Apr 30, 2026$19.80B$17.82B$8.5500$6.9700
Feb 4, 2026$19.29B$17.94B$7.5400$6.9100
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 2 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$17.60B$5.58B$6.21 (diluted)
Q4 FY2025$19.29B$6.64B$7.39 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Eli Lilly and Company (LLY)?

Short answer

Cash and short-term investments were $4.88B at the Sep 30, 2026 balance-sheet date. Operating cash flow was $11.40B for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Lilly combines high gross and operating margins with substantial earnings and operating cash generation. Cash flow has strengthened markedly, but capital expenditure remains heavy and variable, reflecting a business that is consuming meaningful cash outside ordinary operations.

Liquidity has improved, yet debt remains far above cash and investments. Strong distress and quality screens provide reassurance about current financial resilience, but they do not remove the exposure created by leverage, elevated capital needs and a valuation that prices sales, earnings and free cash flow richly.

Because product sales dominate revenue, a broad slowdown in medicine demand or commercialization would reach the income statement directly. Lilly would then have less room to absorb research spending and capital investment without leaning further on the balance sheet.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Rich valuation — a P/E of 45.83 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$11.40B Sep 30, 2026
Previous quarter · operating cash flow
$10.69B Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$11.40B−$3.18B
Jun 30, 2026$10.69B−$2.93B
Mar 31, 2026$5.33B−$2.33B
Dec 31, 2025$3.22B−$2.55B
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Eli Lilly and Company (LLY)?

Short answer · as of

The next earnings report is expected on Feb 3, 2027. The number it tests is the $35.45 EPS analysts carry for it.

Watch whether the next earnings release preserves the recent pattern of revenue and adjusted earnings exceeding expectations. More important than another beat is whether gross profit and operating profit continue rising faster than research and selling costs while net income resumes its advance.

Operating cash flow should also be judged against capital expenditure rather than in isolation. Continued cash accumulation alongside heavy investment would support the current expansion; weaker cash conversion or renewed liquidity erosion would make the debt load more consequential.

Management has tied its raised margin and earnings outlook to higher revenue. Delivery against that linkage would confirm that added medicine sales are converting into operating leverage rather than being absorbed by commercialization, research and acquired development charges.

What management is planning

Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.

  1. We will share our 2027 financial guidance on our Q4 call in January.

    Lucas E. Montarce ·

  2. Beginning with The US revenue, we expect sustained volume growth in the incretin market and the full year impact of the Medicare GLP-1 bridge access.

    Lucas E. Montarce ·

2 more statements are quoted under Upcoming events

5 · Peer comparison

How does Eli Lilly and Company compare with its peers?

Short answer

Eli Lilly and Company's score ranks 1st of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Lilly differs from an early-stage drug developer because it already markets a broad portfolio across several therapeutic areas and generates substantial profit and cash while continuing to spend heavily on research. The economic engine is commercial medicine volume, not milestone payments: collaboration revenue is comparatively small.

Against other mature pharmaceutical businesses, the notable combination is rapid recent growth, unusually strong margins, heavy reinvestment and a premium market valuation. That mix can reward sustained commercialization success, but it also leaves less room for weakening growth or cash conversion.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eli Lilly and Company (LLY) — this page$1351.12$1.20T98
Sanofi (SNY) Same industry, near in market value$47.12 Nov 18, 2026$113B87 5-pillar Nov 18, 2026
AstraZeneca PLC (AZN) Named competitor$175.41 Nov 19, 2026$272B85 5-pillar Nov 18, 2026
Bristol-Myers Squibb Company (BMY) Same industry, near in market value$58.34 Nov 19, 2026$119B85 5-pillar Nov 18, 2026
Amgen Inc. (AMGN) Same industry, near in market value$443.89 Nov 18, 2026$240B84 5-pillar Nov 18, 2026
Johnson & Johnson (JNJ) Named competitor$267.14 Nov 19, 2026$643B83 5-pillar Nov 18, 2026
AbbVie Inc. (ABBV) Named competitor$283.54 Nov 19, 2026$501B83 5-pillar Nov 18, 2026
Novartis AG (NVS) Named competitor$155.21 Nov 18, 2026$293B82 5-pillar Nov 18, 2026
GSK plc (GSK) Same industry, near in market value$47.82 Nov 19, 2026$95.9B77 5-pillar Nov 18, 2026
Gilead Sciences, Inc. (GILD) Same industry, near in market value$168.98 Nov 18, 2026$210B72 5-pillar Nov 18, 2026
Merck & Co., Inc. (MRK) Named competitor$132.81 Nov 19, 2026$327B69 5-pillar Nov 18, 2026
Pfizer Inc. (PFE) Same industry, near in market value$28.06 Nov 18, 2026$160B67 5-pillar Nov 18, 2026
Grifols, S.A. (GRFS) Same industry, near in market value$8.20 Nov 19, 2026$5.58B60 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$940.00 – $1650.00
Consensus target
$1442.44
Median target
$1440.00
Revenue estimate
$91.33B
EPS estimate
$35.45

Consensus record · Captured .

Measured against a quoted price of $1351.12 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 16, 2026

Transactions
58
Identified insiders
22
Purchases
0
Sales
4
Other transactions
54

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
87.0% Period end Sep 30, 2026
Previous quarter · ownership
88.9% Prior to period end Sep 30, 2026
Reporting holders
4,755 Period end Sep 30, 2026
Previous quarter · holders
4,817 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Lilly Endowment INC90,066,978
Blackrock, INC.67,936,153
Vanguard Capital Management LLC53,921,209
Pnc Financial Services Group, INC.51,295,197
State Street Corp36,848,565

Tracked investors

Which of the 16 named investors we follow held LLY in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
ARK InvestCathie WoodQ3 20260.72%$124.78MAdded +39.6% shares
Bridgewater AssociatesFounded by Ray DalioQ3 20260.48%$109.60MAdded +8.8% shares
Duquesne Family OfficeStanley DruckenmillerQ3 20260.10%$4.40MTrimmed −69.3% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Eli Lilly and Company (LLY)?

Read these with our analysis →

Eli Lilly and Company Healthcare Stock: Key Questions Answered

The last 2 questions are answered from this page's own dated data, not from the research.

What does Lilly sell beyond diabetes medicines?

Lilly also markets oncology drugs, autoimmune and inflammatory treatments, and medicines for neurological disorders and pain. These established therapeutic areas make the company broader than a diabetes-only franchise.

How important is collaboration revenue to Lilly?

Collaboration and other revenue is ancillary beside product sales. Lilly's reported growth therefore rests primarily on commercial demand for its medicines rather than partner payments.

Is Lilly increasing research spending while profits grow?

Annual research spending has risen alongside a much faster expansion in revenue and net income. Recent periods also show research expense remaining substantial as Lilly scales its commercial business.

Why is the Lilly Endowment notable in Lilly ownership?

The Lilly Endowment is the largest named institutional holder, ahead of major asset managers in the disclosed holder list. Institutional ownership also increased in the latest reported period, making large holders especially relevant to the shareholder base.

What is the LLY stock price today?

The last price recorded for Eli Lilly and Company (LLY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the LLY price target?

The analyst consensus price target for Eli Lilly and Company (LLY), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Reviewed by Sedat ANAK, Founder and Editor-in-Chief, on 2026-11-07.

Sources: the source register lists the 85 figures on this page — 2 from SEC filings and earnings calls, 71 from Financial Modeling Prep (FMP), 5 with no recorded source, 5 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Cash, investments and debt; Trailing twelve-month ratio set
  • 1. What is Eli Lilly and Company (LLY), and what does it report?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands)
  • 2. What do the latest results show for Eli Lilly and Company (LLY)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Most recent periodic reports
  • 3. What are the financial strengths and risks for Eli Lilly and Company (LLY)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash against market value; Trailing twelve-month ratio set; Distress and quality screens; Revenue by segment
  • 4. What should you watch next at Eli Lilly and Company (LLY)?: Next earnings report; Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Management outlook — dated call excerpts
  • 5. How does Eli Lilly and Company compare with its peers?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set; Cash against market value
  • FAQ: What does Lilly sell beyond diabetes medicines?: Business description
  • FAQ: How important is collaboration revenue to Lilly?: Revenue by segment
  • FAQ: Is Lilly increasing research spending while profits grow?: Annual revenue and net result (USD millions); Quarterly income statement (USD thousands)
  • FAQ: Why is the Lilly Endowment notable in Lilly ownership?: Largest 5 institutional holders; Institutional ownership (13F)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold LLY

Funds in our ETF coverage that list LLY among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
PBPH ETF13.85%
VHT ETF12.70%
ProShares - Ultra Health Care (RXL)10.22%
IXJ ETF10.08%
iShares Evolved U.S. Innovative Healthcare ETF (IEIH)7.55%
Simplify Health Care ETF (PINK)7.00%
Pathfinder Focused Opportunities ETF (PFOE)5.17%
Jensen Quality Growth ETF (JGRW)4.86%
PGIM Jennison Focused Growth ETF (PJFG)4.42%
SNPG ETF4.24%